Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** composed of **succinic acid**, **inosine**, **taurine**, and **methionine**, all of which act as metabolic agents with antioxidant and neuroprotective properties. Each ingredient in the combination has recognized roles in cellular metabolism and neuroprotection: - **Succinic acid** is a Krebs cycle intermediate involved in energy production and has antioxidant effects. - **Inosine** is a nucleoside that can support ATP synthesis and has neurotrophic properties. - **Taurine** is an amino acid implicated in membrane stabilization, osmoregulation, and neuroprotection. - **Methionine** is an essential amino acid involved in methylation reactions and cellular metabolism. Similar combinations with succinic acid, inosine, and other metabolic agents (though not taurine and methionine together) have been evaluated for neuroprotective effects, for example, in diabetic neuropathy and liver protection, chiefly due to antioxidant effects and mitochondrial support[1][3]. No unique brand name, code name, or proprietary clinical product is known for this precise four-compound combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on succinic acid + inosine + taurine + methionine.